MLchartDataset catalogue

Orgovyx

Term · Oncology and biomedicine · MLC-T-ONC-006150

A drug used to treat adults with advanced prostate cancer. Orgovyx binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland, which blocks the pituitary gland from making the hormones follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This causes the testicles to stop making testosterone. Orgovyx may stop the growth of cancer cells that need testosterone to grow. It is a type of GnRH antagonist. Also called relugolix.

Table 1. Record
IdentifierMLC-T-ONC-006150
FieldOncology and biomedicine
Synonymsrelugolix
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-006150",
  "term": "Orgovyx",
  "field": "Oncology and biomedicine",
  "definition": "A drug used to treat adults with advanced prostate cancer. Orgovyx binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland, which blocks the pituitary gland from making the hormones follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This causes the testicles to stop making testosterone. Orgovyx may stop the growth of cancer cells that need testosterone to grow. It is a type of GnRH antagonist. Also called relugolix.",
  "synonyms": [
    "relugolix"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/orgovyx/"
}

Record 12,345 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.